Genfit S.A. is a biotechnology company focused on developing innovative therapeutic and diagnostic solutions for liver diseases and metabolic disorders
With a strong emphasis on research and clinical development, Genfit's proprietary technologies aim to identify and address various health conditions related to liver dysfunction, including non-alcoholic steatohepatitis (NASH) and other hepatic pathologies. The company is committed to advancing the understanding of these diseases and improving patient outcomes through its drug candidates and diagnostic tools, leveraging both its scientific expertise and strategic partnerships in the healthcare sector.
The U.S. FDA has granted accelerated approval for Iqirvo, a novel drug from Ipsen SA and Genfit SA, designed for treating primary biliary cholangitis (PBC). This approval, based on the drug's ability to reduce alkaline phosphatase levels, marks a significant advancement in therapies available for PBC.
Gainers Renalytix Plc (NASDAQ: RNLX) shares surged 48.7% to $3.02 in pre-market trading after the company received FDA De Novo marketing authorization for its KidneyIntelX.dkd prognostic test.
On Friday, FDA's Gastrointestinal Drugs Advisory Committee voted 12 to 2—with two abstentions—that the benefits of Intercept Pharmaceutical Inc's ICPT Ocaliva 25 mg, also known as Obeticholic acid (OCA), don't outweigh the risks in nonalcoholic steatohepatitis (NASH)
Companies Reporting Before The Bell • Northern Technologies (NASDAQ:NTIC) is estimated to report quarterly earnings at $0.18 per share on revenue of $20.40 million.
Gainers NeuroMetrix (NASDAQ:NURO) shares increased by 23.0% to $3.48 during Monday's pre-market session. The company's market cap stands at $24.8 million.
